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ABSTRACT
Mendelian randomization (MR) is an increasingly important tool for
appraising causality in observational epidemiology. The technique
exploits the principle that genotypes are not generally susceptible
to reverse causation bias and confounding, reflecting their fixed
nature and Mendel’s first and second laws of inheritance. The ap-
proach is, however, subject to important limitations and assump-
tions that, if unaddressed or compounded by poor study design, can
lead to erroneous conclusions. Nevertheless, the advent of 2-sample
approaches (in which exposure and outcome are measured in sep-
arate samples) and the increasing availability of open-access data
from large consortia of genome-wide association studies and pop-
ulation biobanks mean that the approach is likely to become routine
practice in evidence synthesis and causal inference research. In this
article we provide an overview of the design, analysis, and
interpretation of MR studies, with a special emphasis on assump-
tions and limitations. We also consider different analytic strategies
for strengthening causal inference. Although impossible to prove
causality with any single approach, MR is a highly cost-effective
strategy for prioritizing intervention targets for disease preven-
tion and for strengthening the evidence base for public health
policy. Am J Clin Nutr 2016;103:965–78.
Keywords: Mendelian randomization, causality, reverse causation,
confounding, observational epidemiology, evidence synthesis
INTRODUCTION
A major goal of applied epidemiology is to reduce the burden
of disease in populations through interventions that target causal
determinants of disease risk. However, because of the limitations
of observational research, robust causal inference is usually not
possible. Although observational studies, such as prospective
cohort studies and case-control studies, can provide evidence
with regard to disease etiology, limitations such as residual
confounding, reverse causation bias, and measurement error
severely constrain the ability to infer causality (1, 2). To get
around such limitations, epidemiologists have traditionally relied
on a set of empirical guidelines, often referred to as the Bradford
Hill criteria (Table 1) (3). If these criteria are satisfied, the ev-
idence for causality may be considered suitably robust to justify
a randomized controlled trial (RCT)5 or public health policies
for disease prevention. The criteria include temporality (expo-
sure must precede disease), a dose-response relation, and
specificity in the exposure-outcome relation (associations with
specific disease outcomes, as opposed to a wide range of out-
comes, are often viewed as more compatible with causality). In
addition, although not formally part of the Bradford Hill criteria,
associations should be independent of known confounders.
However, even the most robust observational evidence, which
typically comes from meta-analyses of prospective studies,
will be susceptible to residual confounding (arising from
measurement error and unknown confounders) and reverse
causation bias (arising from preclinical stage of disease).
The limitations of observational epidemiology are exemplified
by research into vitamin E supplements, vitamin C, and HDL
cholesterol and the risk of coronary artery disease (CAD).
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Although evidence from large meta-analyses of prospective
studies supports an independent inverse association between
HDL cholesterol and the risk of CAD (4), interventions designed
to increase HDL cholesterol have not led to reductions in CAD
incidence (5). Similarly, randomized trials of vitamin C and E
supplementation did not indicate a decreased risk of cardio-
vascular disease (6), despite the evidence from prospective ob-
servational studies that suggested protective effects of these
vitamins (7, 8).
Given that one of the primary rationales for observational
studies is to inform intervention strategies for improving public
health, such failures should be of major concern to researchers,
funders, and public health policy makers. Moreover, given the
expense and difficulty of designing RCTs and other prevention
strategies, any approach that can strengthen causal inference, and
so help prioritize intervention targets for disease prevention, is
likely to save considerable resources. Mendelian randomization
(MR) approaches have been developed with this context in mind
and address many of the aforementioned limitations of obser-
vational epidemiology.
MENDELIAN RANDOMIZATION
MR is a relatively new form of evidence synthesis and causal
inference that is of growing importance in observational epi-
demiology (9). The approach can be viewed as an application of
instrumental variable analysis, a technique originally developed
in the field of econometrics (10), and exploits the principle that
genotypes are not generally associated with confounders in the
population and should be immune to reverse causation bias.
These properties reflect both the fixed nature of genetic variants
as well as Mendel’s first and second laws of inheritance. The key
steps in the approach involve finding genetic polymorphisms
to use as proxies, or “instruments,” for a target exposure and
then testing the association of the genetic instrument with the
outcome of interest (9, 11). An important advantage of the
approach, which is of particular relevance to nutritional epi-
demiology, is that genotypes can be measured with very high
accuracy and reflect long-term patterns of exposure. Thus, MR
approaches are less susceptible to biases arising from mea-
surement error.
For example, there is little doubt that circulating plasma
concentrations of cholesterol are a causal determinant of risk for
CAD. It is therefore widely accepted that genes involved in
cholesterol pathways should be associated with the risk of CAD,
as is observed empirically (12). Similarly, genes involved in
smoking-related pathways should be associated with the risk of
lung cancer. Formal approaches for estimating a causal ef-
fect include scaling the gene-outcome association to reflect
a unit change in the exposure, which allows easier comparison
with other estimates, such as those based on differences in
the exposure from observational studies. Thus, if a genetic
polymorphism is associated with a 0.5-SD change in cholesterol
as well as a log OR for CAD of 0.1, this implies a log OR of 0.2
per 1-SD change in cholesterol (i.e., 0.1/0.5 = 0.2, known as
a Wald ratio estimate).
Reflecting its growing importance, MR has been used to ad-
dress the causal relevance of a wide range of modifiable expo-
sures for risk of major noncommunicable diseases, including
C-reactive protein (CRP) (13, 14), HDL cholesterol (15), uric
acid (16) and triglycerides (17). Results from MR studies gen-
erally mirror those based on RCTs. For example, genetic proxies
for HDL cholesterol are not generally associated with the risk of
CAD (15, 18), consistent with the clinical trial evidence dis-
cussed above (5). In contrast, both genetic proxies for lower LDL
cholesterol and interventions designed to lower LDL cholesterol
are robustly associated with a lower risk of CAD (12, 19),
providing particularly strong evidence for causality.
MR is, however, subject to important assumptions and limi-
tations, which require careful consideration to avoid erroneous
conclusions. The most important assumption pertains to the
specificity of the gene-outcome association. Valid causal in-
ference requires that the association between gene and outcome
occurs exclusively through the hypothesized exposure. More
formally, the genetic instrument 1) must be associated with the
exposure, 2) should be independent of the outcome conditional
on the exposure and confounders, and 3) should not be associ-
ated with confounders of the exposure-outcome association
(20–22) (Figure 1).
Assumption 1
Valid causal inference in an MR study requires a true asso-
ciation between the genetic instrument and the exposure of in-
terest. If this assumption is violated, lack of association between
the genetic instrument and outcome may erroneously be inter-
preted as evidence against a causal association between exposure
and outcome. Violation of this assumption is less likely when
using biologically plausible genetic polymorphisms—for ex-
ample, using variation in the gene for CRP as a proxy for CRP
concentrations. Assumption 1 is the only 1 of the 3 assumptions
that can be directly tested.
Assumption 2
Valid causal inference requires that genetic instruments be
independent of the outcome, conditional on the exposure and
confounders of the exposure-outcome association. In other
words, the effect of the genetic instrument on the outcome must
be mediated exclusively by the exposure in question and there
must be no direct effects. A direct effect is defined as a causal
pathway between the genetic instrument and outcome that does
not involve the hypothesized exposure. This assumption is de-
scribed as “the exclusion restriction” in econometrics. Although
it may be informative to check whether statistical adjustment for
the exposure leads to attenuation of the gene-outcome relation
(22), this adjustment can lead to collider bias (Figure 2) (24).
Stratification of an MR analysis by exposure subgroups leads
to a similar bias (see example below on gene-exposure in-
teractions). The bias occurs when genotypes are not randomly
distributed within the exposure subgroup strata, which may
occur even if the genotype is randomly distributed in the
population (24). The interpretation of such analyses is further
undermined by potential measurement error in the exposure
(25–28). Thus, complete attenuation of the genetic association
with the outcome would not be expected even for a valid genetic
instrument.
Direct effects can be introduced by a number of factors, in-
cluding horizontal pleiotropy, linkage disequilibrium among gene
loci (a known violation of Mendel’s second law of inheritance),
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and population stratification (9, 11, 29, 30). Horizontal pleiot-
ropy occurs when a genetic variant affects multiple traits
through separate pathways. Vertical pleiotropy, also known as
mediation, in which a genetic variant is associated with multi-
ple traits on the same pathway, is less problematic for MR
studies. Linkage disequilibrium describes the correlation be-
tween genetic variants, typically for variants physically close
together on the same chromosome. Population stratification
occurs when subgroups within a sample have different genetic
ancestries. These phenomena can introduce genetic confounding
into an MR study.
Assumption 3
The genetic instruments used in an MR study should not be
associated with confounders (measured or unmeasured) of the
exposure-outcome relation. Such associations can, however,
occur by chance, especially when using weak instruments and
small samples, a phenomenon known as weak instruments bias
(31). Horizontal pleiotropy, linkage disequilibrium, and pop-
ulation stratification, as described above, can also induce asso-
ciations between genetic instruments and confounders.
LIMITATIONS OF MR STUDIES
In addition to the aforementioned assumptions and potential
violations, MR is susceptible to other important practical and
theoretical limitations. These include the difficulty of finding
genetic instruments for hypothesized exposures, low statistical
power, “winner’s curse,” limited biological understanding of
gene-exposure associations, trait heterogeneity, canalization,
and limitations of estimating associations for binary outcomes.
Difficulty of finding genetic instruments
Finding genetic polymorphisms to use as genetic instruments
in an MR study is becoming ever more feasible with the growing
proliferation of genome-wide association studies (GWASs). In a
GWAS, the association of hundreds of thousands to millions
of genetic variants, typically single nucleotide polymorphisms
(SNPs), are tested for an association with a trait of interest.
Finding suitable genetic instruments can, however, be chal-
lenging. For example, in our MR studies of lung cancer, we found
that only 57% of putative risk factors were “instrumentable” (i.e.,
were subject to known associations with SNPs). To date, most
large-scale GWASs have been conducted on comparatively
easy or inexpensive traits to measure.
Low power
Because genetic polymorphisms typically explain only a small
fraction of the total variance in traits, MR studies require very
large sample sizes for sufficient statistical power. For example,
when a genetic instrument explains 1% of the variation in a trait,
which is not unusual,w9500 cases and equal number of controls
will be required for 80% power to detect an OR of 1.5 per SD
change in the exposure, assuming a P value threshold of 0.05 for
significance (32). For individual polymorphisms, the variance
explained will typically be ,1%, which is why it is usually
advisable to combine multiple polymorphisms into a single al-
lele score, so as to maximize the explanatory power of the
instrument. Strong multigene instruments are, however, the ex-
ception rather than the rule. For example, although 97 genetic
loci have been implicated in BMI by GWASs, these loci together
account for just 2.7% of the total variance in BMI (33).
Winner’s curse
When GWASs report evidence of association for a trait at
a specific genomic region, involving multiple, sometimes hun-
dreds, of SNPs, they typically select the SNP with the smallest
P value as the lead SNP and do not report the associations for
other significant SNPs. This practice generally leads to over-
estimation of the SNP-trait effect, also known as the winner’s
curse or Beavis effect (34). The overestimation occurs because
of chance correlation between SNPs and confounders in the
GWAS discovery stage. If the GWAS discovery and MR studies
are independent, the winner’s curse will not affect the power or
FIGURE 1 Basic principles of Mendelian randomization. The target
exposure (E) is causally associated with the outcome (O) if the following
conditions are held: 1) the genetic variant (G) is associated with E; 2) there is
no association between G and O, except through E; and 3) G is independent
of any measured or unmeasured confounding factors (C). The gray lines
indicate potential violations of Mendelian randomization assumptions and
must be absent in order for G to be a valid instrumental variable. Reproduced
from reference 23 with permission.
TABLE 1
Empirical criteria for appraising causality in epidemiology1
Criteria Methods of appraising criteria
Temporality Exposure precedes disease
Biological
gradient
A dose-response relation between exposure and
disease is present
Specificity Greater specificity is often viewed as more
compatible with causality—for example, when an
exposure is associated with a single outcome as
opposed to multiple outcomes




A similar exposure-disease association is seen in
independent studies
Strength Weak associations are less likely to be causal
Plausibility A plausible mechanism for the association exists
Coherence Epidemiologic findings are compatible with
laboratory evidence
Analogy Effects exist for similar factors
Experiment Interventions targeting the exposure are associated
with reduced disease burden in the population
1All of the criteria refer to Bradford Hill criteria (3), with the exception
of “independence.”
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size of a causal hypothesis test, but it will bias MR estimates
toward the null. To illustrate this, consider the Wald ratio, a com-
mon approach for deriving causal estimates from summary data
with a single SNP. The Wald ratio is the coefficient of the
SNP-outcome association divided by the coefficient of the
SNP-exposure association. Thus, overestimation in the denominator,
e.g., due to winner’s curse, will result in an underestimation of the
ratio but only when both samples are independent. When the dis-
covery and MR analysis samples are the same, both the numerator
and denominator will be overestimated.
Poor biological understanding
Although thousands of SNP-trait associations have been dis-
covered by GWASs, little is typically understood about the un-
derlying biology or mechanisms of association. This limitation can
sometimes lead to counterintuitive results. For example, oxidative
processes are strongly implicated in atherosclerosis, the major driver
of CAD, and cardioprotective effects have therefore been hypoth-
esized for antioxidants. However, contrary to this expectation, the
R213G genetic polymorphism in the gene for extracellular super-
oxide dismutase (EC-SOD), an extracellular scavenger of super-
oxide anions, is associated with higher circulating concentrations of
EC-SOD as well as a higher risk of CAD (35). However, the higher
concentration in blood is thought to result from depletion of EC-
SOD in the arterial wall. Thus, the R213G genetic polymorphism
should be associated with a reduced concentration of EC-SOD at the
site of atherosclerosis, which is ofmore direct biological relevance to
CAD. Without this additional biological knowledge, the positive
association between circulating EC-SOD and CAD risk could na-
ively be interpreted as evidence supporting a cardio-deleterious role
for antioxidants (Figure 3).
A similarly counterintuitive result is seen in MR studies of the
IL-6 receptor (IL-6R) and CAD (36, 37). The p.Asp358Ala
genetic polymorphism at the IL6R gene is associated with higher
circulating concentrations of IL-6R and IL-6 and reduced odds
of CAD, contrary to the expectation from observational studies
in which a higher circulating concentration of IL-6 is associated
with higher risk. The paradox can be explained by reduced
membrane-bound IL-6R, leading to increased circulating con-
centrations of IL-6R and IL-6 and reduced IL-6 cell signaling. In
other words, the higher circulating concentrations of IL-6 in
carriers of p.Asp358Ala do not stem from increased production
of the protein but rather from reduced cellular binding of IL-6.
As with the EC-SOD example, biological knowledge about
the IL-6 pathway prevented erroneous causal inference. Un-
fortunately, such detailed biological knowledge is unlikely to
apply to the majority of known gene-trait associations.
Trait heterogeneity
Genetic polymorphisms are sometimes associated with mul-
tiple aspects or dimensions of a single trait (Figure 3). Such trait
heterogeneity does not preclude causal inference but it does un-
dermine the ability to infer causality for particular dimensions of
heterogeneous traits. For example, a copy number variant at exons
4 and 5 of the apolipoprotein(a) gene (LPA) affects both the size
and expression levels of the protein product, apolipoprotein(a)
[apo(a)]. Posttranslationally, apo(a) is covalently bound to LDL
to form lipoprotein(a) [Lp(a)], a well-established risk factor for
CAD. Observationally, smaller protein size and higher concen-
trations of Lp(a) are associated with higher CAD risk (38, 39).
MR studies suggest that the associations reflect causality, be-
cause genetic polymorphisms associated with Lp(a) concentra-
tion are associated with CAD (40, 41). However, the association
between Lp(a) concentration and CAD is potentially con-
founded by apo(a) size, because the size-determining copy
number variant could affect CAD independently of its effect on
Lp(a) concentration (42–47). Thus, although there is little
doubt that a causal association exists between the Lp(a) par-
ticle and CAD, ascertaining the particular dimension of Lp(a)
driving the association with CAD is undermined by Lp(a)
heterogeneity (Figure 3).
There are parallels between the above example for Lp(a) and
the problematic interpretation of the findings for IL-6R and
EC-SOD, described above, which were also subject to confounding
by different dimensions of the same trait (Figure 3). For example,
in the case of IL-6R, the association between circulating IL-6R
and CAD was confounded by reduced IL-6 cell signaling. Only
biological knowledge was able to resolve the particular di-
mension of the IL-6 pathway that was causally relevant to in-
creased CAD risk.
Trait heterogeneity may also limit MR studies of smoking, as
shown by the example of the nicotinic receptor gene cluster on
chromosome 15 [cholinergic receptor nicotinic a 5 subunit - a 3
subunit - b 4 subunit (CHRNA5-A3-B4)]. Each copy of the
minor allele of rs1051730 (or equivalently rs16969968), which
resides within the gene cluster, is associated with 1 extra ciga-
rette smoked per day. The latter behavior is, however, only one
among several dimensions of smoking behavior that affect to-
bacco exposure (48). Smokers may vary in their depth of in-
halation, the number of puffs they take per cigarette, how much
of the cigarette they smoke, the type of cigarette they smoke,
and number of years spent smoking, all of which will affect total
lifetime exposure to tobacco (Figure 3). Thus, it is unlikely that
the association between the nicotinic receptor and tobacco
exposure is mediated exclusively by cigarettes smoked per
day. Heterogeneity in smoking behaviors may explain why
rs1051730 and rs16969968 are more strongly associated with
cotinine (an objective biomarker of tobacco exposure) than with
daily cigarette consumption (49). Although this heterogeneity in
behavior does not invalidate the use of CHRNA5-A3-B4 as
a genetic instrument for smoking, it does undermine its use for
estimating causal effects for particular dimensions of smoking
behavior (48). In other words, we may still be able to infer that
a causal association exists but be unable to infer the precise
magnitude of the causal effect.
Canalization
During development, compensatory processes may be gen-
erated that counter the phenotypic impact of the genetic variant
being used as an instrument for an exposure of interest (11).
FIGURE 2 Collider bias. Conditioning on X, whether by design or
analysis, induces a biased association between G and O, through C. C,
confounder; G, genetic variant; O, outcome; X, exposure.
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Theoretically, one could expect such developmental buffering to
result in attenuated or null associations between the genetic
instrument and outcome. Canalization is likely to be less prob-
lematic for exposures adopted after fetal development, such as
behavioral traits like smoking, and more of a problem for severe
protein-coding mutations expressed during fetal development.
No general approaches are available for appraising or avoiding
canalization.
Estimating associations for binary outcomes
If the outcome is binary (e.g., a disease outcome) and par-
ticularly if the genetic associations with the outcome are esti-
mated in a case-control setting, then estimates of theMR effect of
exposure on outcome may only be approximate (50). If exposure
measurements are obtained after disease diagnosis in a case-
control setting, then the genetic associations with the exposure
could be biased by reverse causation unless the gene-exposure
association is derived from controls only (21). Estimates will be
less biased in a nested case-control study where measurements
are obtained at baseline, but participants should still be weighted
so that the case-control sample better represents the target
population (51). In addition, because of the phenomenon of
“noncollapsibility,” ORs have limited generalizability (52–54).
Noncollapsibility, which does not apply to other etiologic
estimates such as HRs or risk differences, derives from the
mathematics of how an OR is calculated (54). In practice, non-
collapsibility means that ORs cannot be used to predict the precise
impact of an intervention on specific subgroups in a popula-
tion and can only be used to predict the population-averaged
FIGURE 3 Trait heterogeneity and causal inference in Mendelian randomization studies. The figure shows how trait heterogeneity can undermine
causal inference in Mendelian randomization studies. (A) The association of Lp(a) concentration with the risk of CAD is confounded by Lp(a) size; (B)
the associations of cIL6 and cIL6R concentrations with risk of CAD are confounded by mIL6R; (C) the association between cEC-SOD and CAD is
confounded by aEC-SOD; and (D) the association between rs1051730 and disease is likely to be mediated by multiple dimensions of smoking behavior.
aEC-SOD, arterial/endothelial extracellular superoxide dismutase; cEC-SOD, circulating extracellular superoxide dismutase; CAD, coronary artery
disease; CHRNA5-A3-B4, cholinergic receptor nicotinic a 5 subunit - a 3 subunit - b 4 subunit, nicotinic receptor gene cluster; cIL6, circulating
IL-6; cIL6R, circulating IL-6 receptor; CNV, copy number variant; EC-SOD, extracellular superoxide dismutase; LD, linkage disequilibrium; Lp(a),
lipoprotein(a); LPA, apolipoprotein(a) gene; mIL6R, membrane-bound IL-6 receptor; SNP, single nucleotide polymorphism; SOD3, superoxide dismutase
3 gene.
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causal effect (53, 54). The above considerations do not af-
fect the ability of an MR study to draw unbiased conclusions
about whether a target exposure has a causal effect on an out-
come (53), but they do affect the magnitude of the estimated
effect (54).
CONSTRUCTING A GENETIC INSTRUMENT
The most important step in an MR study is finding a genetic
instrument to use as a proxy for the target exposure. In practice,
most genetic instruments used to date have been based on SNPs,
but in principle, any kind of genetic polymorphism could be
used, including copy number variants (41). In the first step of
constructing a genetic instrument it is important to find genetic
polymorphisms robustly associated with the exposure of in-
terest, for which there are 2 broad approaches. One approach is
to use polymorphisms with proven or plausible biological ef-
fects on the target exposure—for example, using SNPs at the
CRP, alcohol dehydrogenase 1B (ADH1B), and IL6R genes as
instruments for CRP, alcohol, and IL-6R, respectively. Results
based on such instruments can be particularly compelling
because they may be less susceptible to pleiotropy and
more likely to reflect the target exposure. The second general
approach exploits the increasing availability of results from
GWASs. Hundreds of such studies have been conducted to
date, and their findings are curated by the National Human
Genome Research Institute’s GWAS catalog. Currently there
are .10,000 SNP-trait associations curated by the catalog,
corresponding to w1400 unique phenotypes. In principle,
SNPs curated by the catalog can be used to construct genetic
instruments for exposures of interest.
An important caveat is that little of the underlying mechanisms
of the associations curated by the catalog will typically be well
understood, which increases the potential for pleiotropy and
counterintuitive results (as discussed above). In addition, many of
the SNPs curated by the catalog have not been replicated in
independent samples, increasing the potential for false positives
as well as winner’s curse bias. On the other hand, the number of
SNPs available for instrumentation is likely to be far greater
when relying on GWASs, as opposed to hypothesis-driven ap-
proaches. When multiple SNPs are available, these can be
combined into a single genetic instrument to increase the sta-
tistical power of an MR study.
DIFFERENT DESIGN STRATEGIES FOR MR
In a broad sense, any approach that uses genetic information to
make inferences about the causal relation between traits could be
considered part of the MR family. As a result, there are many
different design strategies for MR (Table 2). Some of the
strategies provide estimates of the magnitude of the causal ef-
fect, whereas others only provide evidence on whether a causal
association exists. The strategies considered below can be ap-
plied equally to continuous and binary (e.g., disease) outcomes,
although, as noted above, estimation in the binary setting may
only be approximate.
Gene-exposure plus gene-outcome association
In the simplest study design, the existence of a gene-exposure
and a gene-outcome association implies a causal effect of exposure
on outcome. For example, in one study, genetic polymorphisms at
the LPA gene were associated with both Lp(a) concentration and
the risk of CAD (40). Although the magnitude of the causal effect
of Lp(a) on CAD was not formally estimated, these findings in-
dicate that the positive association between Lp(a) concentration
and CAD risk (39) reflects causality. The assumptions behind this
approach can be viewed as less stringent in comparison with tech-
niques that attempt to estimate the magnitude of the causal asso-
ciation, described below.
One-sample MR with individual participant data
One-sample MR is the standard implementation of MR in
a single data set with data on the SNPs, exposure, and outcome
for all participants. With individual participant data, the causal
effect of the exposure on the outcome can be estimated by using
2-stage least-squares (2SLS) regression, a method originally
developed in the field of econometrics (55). In the first stage, the
exposure of interest is regressed on the genetic instrument, which
can either be a single SNP, multiple SNPs, or an allele score based
on multiple SNPs (e.g., the sum of the number of exposure-
increasing alleles). The predicted values of the exposure are taken
from the first-stage regression model. In the second stage, the
outcome of interest is regressed over the predicted values of the
exposure by using either linear or logistic regression, depending
on whether the outcome is a continuous or binary variable. The
b-coefficient from the second stage can be interpreted as the
change in the outcome (for logistic regression, the log OR for
TABLE 2
Different design strategies for MR1
Study design Test Comments
G-X + G-Y Implies X/Y No estimation of magnitude of causal effect
One-sample MR Various hypotheses Requires individual-level data; lower power; MR estimates
are biased toward the confounded observational
association by weak instruments
Two-sample MR Various hypotheses Individual-level or summary data; greater power (due
to greater potential sample sizes);MR estimates are biased
toward the null by weak instruments
Bidirectional MR X/Y and Y/X Assesses causation in both directions
Two-step MR X/M/Y Tests mediation in a causal pathway
G3E X/Y
(relation is dependent on environment variable)
Able to detect direct effects (a violation of assumption
2 of MR)
1G3E, gene-environment interaction; G-X, SNP-exposure association; G-Y, SNP-outcome association, M, mediator; MR, Mendelian randomization;
SNP, single nucleotide polymorphism; X, hypothesized exposure; Y, outcome variable of interest.
970 HAYCOCK ET AL.
 at UNIVERSITY O
F BRISTO
L CANYNG







disease) per unit increase in the exposure due to the genetic
instrument. When using an allele score, it is typical for the SNPs to
be weighted according to the size of the gene-exposure effect from
an independent study. When implementing 2SLS, it is important
that the samples used for discovering the genetic instrument or in-
struments are independent of the samples used for the MR analysis.
Overlap between discovery and analysis samples compounds the
effect of weak instruments, biasing causal estimates toward the
confounded observational association. 2SLS can be implemented by
using standard statistical software, including “ivregress” in STATA
(StataCorp) and “ivpack” in R (R Foundation).
Summary data
Summary data are summarized genetic associations with the
exposure and outcome (usually in the form of b-coefficients and
SEs) often provided by consortia when sharing individual-level
data are impractical. A common approach for deriving causal
estimates from summary data with a single SNP is the Wald
ratio, in which the coefficient of the SNP-outcome association is
divided by the coefficient of the SNP-exposure association. If
the outcome is a binary disease trait, the Wald ratio can be in-
terpreted as the log OR for disease per unit increase in the ex-
posure due to the SNP. This gives the same estimate as the 2SLS
method with a single SNP. The SE of the Wald ratio can be
estimated as the SE of the gene-outcome association divided by
the coefficient of the gene-exposure association, but this does
not take into account uncertainty in the latter. Alternatively, the
SE of the Wald ratio can be approximated by the delta method,
which makes allowance for uncertainty in the gene-exposure and
gene-outcome relations (56).
A number of approaches exist for combining summary data
across multiple SNPs. A common approach is to use weighted
linear regression, in which the coefficient of the gene-outcome
association is regressed on the coefficient of the gene-exposure
association, with weights derived from the inverse variance of the
gene-outcome association, and with the intercept constrained to
zero. The slope from this model can be interpreted as the MR
estimate of the effect of the exposure on the outcome. The slope
of the relation between the gene-outcome and gene-exposure
associations can also be estimated by maximum likelihood (57).
Alternatively, Wald ratios can be estimated for each SNP sep-
arately and combined by fixed- or random-effects meta-analysis.
Methods based on summary data generally require that the SNPs
be completely independent or that the correlation between
SNPs be taken into account—for example, through a variance-
covariance matrix of the SNPs based on 1000-genomes data
(58). The effect estimates from all of these approaches should
be equivalent to the effect estimated by an allele score in
2SLS when sample sizes are large and SNPs are completely
independent.
Two-sample MR
Two-sample approaches are a novel extension to 2SLS that
greatly increase the scope of MR, because they allow for greater
sample sizes and thus greater statistical power. Contrary to a
2SLS approach, in which the gene-exposure and gene-outcome
relations are estimated in the same sample, 2-sample approaches
derive the estimates from separate samples (e.g., separate
GWASs of exposure and outcome) (57, 58). The major as-
sumptions of the approach are that the gene-exposure and gene-
outcome associations should be estimated in nonoverlapping
samples and should be representative of the same population,
practically defined as being of similar age and sex distribution
and the same ethnic group. When the latter assumption is vio-
lated, the approach may still provide evidence on whether
a causal association exists but not necessarily on the precise
magnitude of the causal effect. In a 1-sample setting, bias of
causal estimates due to weak instruments is toward the con-
founded observational association, whereas in a 2-sample setting,
bias is toward the null. Another advantage of the approach is that
access to individual-level data is not required and causal esti-
mates can be derived from summary data alone (57). An im-
portant consideration is that the gene-exposure and gene-outcome
associations should be coded relative to the same effect allele.
Harmonization of the effect alleles is usually straightforward but
may be problematic for palindromic SNPs (i.e., G/C and A/T
SNPs), which look the same on both DNA strands. If the ref-
erence strand is unknown in one or both samples, it can be
inferred from the frequency of the effect allele.
Two-sample approaches exploit the growing availability of
summary data from large consortia of GWASs, such as the
GIANT (Genetic Investigation of ANthropometric Traits) con-
sortium, the Global Lipids Genetics Consortium, the Interna-
tional Consortium for Blood Pressure, and the CARDIoGRAM
(Coronary ARtery DIsease Genome wide Replication and Meta-
analysis) consortium. Table 3 provides a nonexhaustive list of
TABLE 3
Publicly available GWAS summary data1
Trait Consortium
Alzheimer disease International Genomics of Alzheimer’s
Project
Anorexia nervosa Genetic Consortium for Anorexia Nervosa
Anthropometric traits Early Growth Genetics Consortium
Anthropometric traits Genetic Investigation of ANthropometric
Traits (GIANT)
Autism Psychiatric Genomics Consortium
Bipolar disorder Psychiatric Genomics Consortium
Blood pressure International Consortium for Blood Pressure
Coronary artery disease Coronary ARtery DIsease Genome wide
Replication and Meta-analysis
(CARDIoGRAM)
Crohn disease International Inflammatory Bowel Disease
Genetics Consortium
Education Social Science Genetics Association
Consortium
Glycemic traits Meta-Analyses of Glucose and Insulin-
related traits Consortium (MAGIC)
Lipids Global Lipids Genetics Consortium
Major depressive disorder Psychiatric Genomics Consortium
Osteoporosis GEnetic Factors for OSteoporosis
Consortium (GEFOS)
Schizophrenia Psychiatric Genomics Consortium
Smoking Tobacco and Genetics Consortium
Type 2 diabetes DIAbetes Genetics Replication And
Meta-analysis (DIAGRAM)
Ulcerative colitis International Inflammatory Bowel Disease
Genetics Consortium
1GWAS, genome-wide association study.
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publicly available summary data. A list of available studies can
also be found on the website of the psychiatric genomics con-
sortium (59) and in Burgess et al. (57).
Bidirectional MR
In bidirectional, or reciprocal, MR, instruments for both ex-
posure and outcome are used to assess the causal association in
both directions (Figure 4). For example, Timpson et al. (60)
used this approach to assess the direction of causation between
circulating CRP concentrations (instrumented by the rs3091244
SNP in the CRP gene) and BMI [instrumented by the rs9939609
SNP in the fat mass and obesity associated (FTO) gene]. Within
this context, the authors showed that CRP is likely to be
a marker of increased adiposity, rather than the reverse.
This approach allows further dissection of the directional
association between an exposure and outcome and can be ex-
tended to networks of correlated phenotypes (60–62). However,
a potential limitation is that the approach assumes that the
causal association occurs in one direction, such that the impact
of feedback loops between exposure and outcome cannot be
addressed.
Two-step MR
Two-step MR, not to be confused with 2-sample MR, uses
genetic instruments to assess mediation in a potentially causal
pathway (Figure 5) (11, 63–65). For example, it may be de-
sirable to know whether blood pressure mediates the association
between BMI and CAD. In the first step, genetic instruments for
BMI are used to assess the causal association between BMI and
blood pressure. In the second step, genetic instruments for blood
pressure are used to assess the causal effect of blood pressure on
CAD risk. Evidence of association in both steps implies some
degree of mediation of the association between BMI and CAD
by blood pressure. The magnitude of the direct and indirect
effects of BMI on CAD can also be estimated (64, 65); however,
this requires the assumptions of linearity and homogeneity in
both the exposure-mediator and exposure-outcome associations
(65). In addition, there should be no interaction between expo-
sure and mediator (i.e., the association of the exposure with the
outcome should not vary by values of the mediator and vice
versa) (65).
Gene-exposure interactions
The existence of a gene-exposure interaction implies that
the association between gene and outcome varies by exposure
status. This can be exploited by MR studies to distinguish
between a direct (pleiotropic) effect of the gene on the out-
come and a causal effect via the exposure. For example, the
CHRNA5-A3-B4 gene cluster is associated with heaviness of
smoking and lung cancer (66). Assuming satisfaction of MR
assumptions, the CHRNA5-A3-B4 genetic cluster should not
be associated with lung cancer in never-smokers. Such an
association would indicate the presence of an alternative
pathway from CHRNA5-A3-B4 to lung cancer that does not
involve smoking (i.e., a direct effect). Gene-exposure in-
teractions have been used to assess the causal relevance of
alcohol for risk of upper digestive cancer and systolic blood
pressure by using genetic polymorphisms at the ADH1B and
aldehyde dehydrogenase 2 (ALDH2) genes, which code for
alcohol dehydrogenase 1B and aldehyde dehydrogenase 2,
respectively (67, 68). These genetic instruments for alcohol
consumption were associated with cancer and blood pressure
in men but not women. Given that all drinkers in the latter
study were male and all nondrinkers female, the results are
consistent with the assumption that the instruments work
exclusively through alcohol metabolism. A potential limita-
tion of using gene-exposure interactions for assessing causal
hypotheses is that stratification into exposure subgroups can
induce noncausal associations between genotype and out-
come as a result of collider bias. For example, in an MR
study of whether milk is causally associated with the risk of
type 2 diabetes (69), genotypes at the gene for lactase,
a known determinant of milk consumption, were associated
with increased risk of type 2 diabetes but only in non–milk
consumers, which the authors attributed to collider bias
(Figure 2).
PRACTICAL STRATEGIES FOR ENHANCING CAUSAL
INFERENCE
Genetic confounding (e.g., due to horizontal pleiotropy) and
limited power are the most important limitations typically faced
in an MR study. In this section we consider a number of practical
strategies for dealing with these limitations and for enhancing
causal inference (summarized in Table 4).
FIGURE 4 Bidirectional Mendelian randomization. If a trait (T1) is
causally associated with another (T2), then the genetic variant associated
with T1 (G1) will be associated with both T1 and T2. However, the reverse
(gray dashed line) will not be true and the genetic variant associated with T2
(G2) will not be associated with T1 (unless the relation is truly bidirectional).
Reproduced from reference 23 with permission.
FIGURE 5 Two-step Mendelian randomization. In step 1 (left diagram),
an SNP (G1), independent of any confounding factors (C), is used as
a genetic proxy for an exposure (E) to test the impact of E on a hypothe-
sized mediator (M) of an E-outcome (O) association. G1 will influence M
only if E is causally related to M (gray dashed line). In the second step
(right diagram), another independent SNP (G2) is similarly used as a proxy
for M to assess the causal association between M and O (gray dashed line).
Reproduced from reference 23 with permission. SNP, single nucleotide
polymorphism.
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Assessment of association with measured confounders
In an MR analysis, the association between the genetic in-
strument or instruments and a wide range of potential con-
founders can be assessed. The MR assumptions can be viewed as
plausible when the number of associations is no greater than
expected by chance, as is generally observed empirically (70). An
exclusive association with the target exposure provides further
evidence supporting the MR assumptions. For example, in an MR
study of CRP and CAD, the genetic instrument for CRP was
associated with CRP concentrations but was not associated with
a wide range of other vascular risk factors (13). However,
a limitation is that associations can only be tested for measured
traits and residual confounding by unknown factors remains
a possibility.
Exclusion of nonspecific genetic instruments
Nonspecific genetic instruments (e.g., SNPs associated with
nontarget exposures as well as the target exposure) can be ex-
cluded in a sensitivity analysis (18). If a genetic instrument
remains associated with an outcome of interest after excluding
nonspecific SNPs, evidence for causality may be strengthened.
On the other hand, this selection strategy could also introduce
bias into an MR study—for example, if the multiple exposures
were on the same causal pathway from SNP to disease. In ad-
dition, deciding that an SNP is “specific” for an exposure of
interest may reflect a lack of statistical power to detect associ-
ations with nontarget exposures rather than true biological
specificity.
Detecting and correcting for pleiotropy by statistical and
graphical tests
The use of multiple genetic polymorphisms as instruments
makes it easier to detect evidence of pleiotropy by statistical and
graphical tests. If the estimate of the causal effect is of a con-
sistent magnitude across multiple independent instruments, then
pleiotropy is considerably less likely to account for the results, as
is observed in MR studies of LDL cholesterol (12). On the other
hand, if the causal effects are not consistent across independent
instruments (e.g., with some genetic instruments showing un-
expectedly large or small effects on the outcome, given the
magnitude of their exposure effect), this could be indicative of
pleiotropy. Formal statistical tests for such heterogeneity include
Cochran’s Q statistic and the likelihood ratio test, which test for
consistency across causal effects estimated by Wald ratios
and likelihood-based methods, respectively (57). When causal
effects have been estimated by 2SLS, heterogeneity across
instruments can be assessed by the Sargan test (71). Heterogeneous
effects can also be visualized by scatterplots of the gene-outcome
and gene-exposure associations and forest plots of Wald ratios
for each independent genetic instrument.
Pleiotropy is also detectable by asymmetry in a funnel plot, in
which theMR estimate is plotted against its precision, and inMR-
Egger’s test, a regression of the gene-outcome on the gene-
exposure associations with the intercept unconstrained to pass
through zero (72) (Figures 6 and 7). The intercept from MR-
Egger regression provides a formal statistical test for the pres-
ence of directional pleiotropy, because when the gene-exposure
association is zero the gene-outcome association should also be
FIGURE 6 Funnel plot of MR causal estimates against their precision. Each data point corresponds to an individual genetic variant. The x axis
corresponds to the coefficient of the gene-outcome association divided by the coefficient of the gene-exposure association (i.e., Wald ratios). The funnel
plot asymmetry is due to some genetic variants having unusually strong effects on the outcome given their low precision. This asymmetry is indicative of
directional pleiotropy. MR, Mendelian randomization.
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zero (Figure 7). The contrary implies the presence of a pathway
between gene and outcome that is not mediated by the exposure
(i.e., a direct effect). The slope from MR-Egger regression corre-
sponds to the exposure-outcome association adjusted for directional
pleiotropy. This approach exploits the idea that bias due to directional
pleiotropy is analogous to publication bias in a meta-analysis and
relaxes the exclusion restriction assumption of MR (assumption 2
discussed above). The method does, however, require other MR as-
sumptions to hold. In particular, the strength of the gene-exposure
association should not correlate with the strength of bias due to
pleiotropy [the so-called Instrument Strength Independent of Direct
Effect (InSIDE) assumption (72)], which could occur if the genetic
proxy correlated with confounders of the exposure-outcome associ-
ation. The InSIDE assumption in MR-Egger may also be violated in
a case-control setting, because outcome-dependent sampling can in-
duce associations between genetic instruments and confounders in the
case-control sample. However, it is unlikely that this would sub-
stantially affect type I error rates, particularly if the disease is rare. An
important additional consideration is that MR-Egger can only detect
evidence of directional pleiotropy. In other words, the effect on the
outcome due to pleiotropy should be in the same direction for each
genetic instrument, consistently biasing the gene-outcome association
upward or downward. Pleiotropic effects in opposing directions will
tend to “balance out” and will therefore be less detectable. An ad-
vantage of the approach is that it gives a valid estimate even if all
genetic instruments are subject to directional pleiotropy.
MR-Egger regression should be considered as a type of
sensitivity analysis rather than as an alternative to the more
common approaches described above. Whereas MR-Egger re-
gression relaxes some MR assumptions for all SNPs, other
sensitivity analyses allow complete violation of MR assumptions
for subsets of SNPs (73–75). For example, a weighted median
estimator provides an estimate of the causal effect if at least
50% of the genetic instruments satisfy MR assumptions (75).
Thus, if ,50% of the genetic instruments are invalid, the
weighted median still gives a valid causal estimate. An advan-
tage of the weighted median and MR-Egger approaches is that
both can be implemented by using summary data, whereas other
similar methods require individual-level data (73, 74). A limi-
tation of MR-Egger is that it tends to suffer from low statistical
power for effect estimation.
INTERPRETATION OF AN MR STUDY
Interpretation of an MR study depends on a number of factors,
including a consideration of whether MR assumptions can
be considered broadly satisfied. It is also common practice to
compare etiologic estimates from observational and MR studies,
but such comparisons should be treated with caution because
there are many circumstances under which the magnitude of
genetic and observational associations could differ. These include
reverse causation and confounding in the observational study but
FIGURE 7 Scatterplot of gene-outcome against gene-exposure associations. Each data point corresponds to an individual genetic variant. The x axis
corresponds to the coefficient of the gene-exposure association. The y axis represents the coefficient of the gene-outcome association. In this example, MR
assumption 2 is violated for each genetic variant such that each variant is subject to horizontal pleiotropy or direct effects. As a consequence, the intercept
from MR-Egger regression does not pass through zero. The intercept from MR-Egger regression is an estimate of the average direct effect across the genetic
variants. The dashed and solid lines correspond to the slopes from IVWand MR-Egger regression, respectively, and can be interpreted as the unit change in the
outcome per unit increase in the exposure due to the genetic variants. Unlike IVW regression, the intercept in MR-Egger regression is not constrained to pass
through zero. IVW, inverse-variance–weighted; MR, Mendelian randomization.
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also the various assumptions and limitations discussed above.
Nevertheless, if an MR study finds strong evidence of association
that persists in sensitivity analyses, and if the strategies discussed
above indicate no major violations of assumptions, then the
association between exposure and outcome can be viewed as
compatible with causality.
A particularly promising application of MR is in the priori-
tization of targets for disease prevention, such as in RCTs. For
example, RCTs of proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors for reducing LDL cholesterol were designed
on the basis of genetic supporting evidence (76, 77). Negative
results from MR studies can also help deprioritize interventions,
as in the case of CRP and CAD (13, 14). An assumption un-
derlying the interpretation and application of MR is the idea that
we can infer causality for other sources of variation (e.g., phys-
iologic, dietary, and therapeutic) on the basis of genetic evidence.
Although there are theoretical situations in which this may not
apply (such as in the case of canalization), the principle is generally
well established in the pharmacologic setting (78). For example,
genetic evidence for causation increases 4-fold across the drug
discovery pipeline, from the preclinical stage to approved drugs
(78). On the basis of this observation, it has been estimated that the
prioritizing of genetically supported targets could double the
success rate of drug development (78).
CONCLUSIONS AND FINAL CONSIDERATIONS
In this article we have considered the design, assumptions, and
limitations of MR, as well as the various approaches and strat-
egies that can be used to strengthen causal inference. The
2-sample strategy described above should prove particularly
useful to epidemiologic studies of nutrition. In one recent GWAS
(79), potential genetic instruments for a wide range of metab-
olites relevant to nutrition were uncovered, including biomarkers
of cofactors and vitamins, carbohydrates, amino acids, xenobi-
otics, peptides, and lipids. In principle, genetic instruments for
biomarkers of nutrition defined in one study could be investigated
in large, easily accessible case-control collections of non-
communicable diseases, such as the CARDIoGRAM consortium
of CAD, by using only summary data (Table 3). The findings
from such studies could subsequently be used to prioritize
promising biomarkers for investigation in follow-up observa-
tional or intervention studies or used to strengthen the evidence
base for public health policies relating to diet. Given the growing
availability of open-access data from large GWAS consortia and
population biobanks, the feasibility of MR studies of modifiable
exposures is likely to increase markedly in the near future.
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